Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ICR Zytiga Royalty Entitlement

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portion of the royalty entitlement relating to the sales of Zytiga drug brand. The royalty entitlement of the Zytiga drug brand, which is an abiraterone, is a prescription medicine that is used along with prednisone to treat men with late-stage metastatic prostate cancer.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Other Business Products and Services
Primary Office
  • London
  • England, United Kingdom

ICR Zytiga Royalty Entitlement Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore ICR Zytiga Royalty Entitlement‘s full profile, request access.

Request full access to PitchBook

ICR Zytiga Royalty Entitlement Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore ICR Zytiga Royalty Entitlement‘s full profile, request access.

Request full access to PitchBook